Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q2 2026 · 10-Q
Revenue$651.00M$651.00M−0.1% vs Q2 2025 Net Income$371.40M$371.40M+16.9% vs Q2 2025 EPS Diluted$13.85$13.85+18.7% vs Q2 2025 Gross Profit$345,800,000+0.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$98,700,000−15.3% Free Cash Flowderived$66,700,000−5.8% Margins · derivedGross margin53.1%+0.1 pt vs Q2 2025
Operating margin11.2%−0.7 pt vs Q2 2025
Net margin57.1%+8.3 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 4, 2026 · 35 d after period end